This week’s episode is part 4 of 5 of a joint mini-series with our friends Two Onc Docs. In today’s episode, we will be recapping the current treatment of resectable NSCLC and discussing KEYNOTE 671, which was presented at ASCO 2023, looking at neoadjuvant chemo+immunotherapy followed by adjuvant immunotherapy. We also discuss the use of the “interaction test,” “multiplicity,” and it’s important role in understanding subgroup analyses. Content: - A quick recap of the current standard of care for resectable lung non-small cell lung cancer - A discussion about KEYNOTE 671 presented at ASCO 2023- We define the "interaction test"- We discuss "multiplicity"Want to read the abstract for yourself? Click here!Episode list: Episode 1 covering covering rectal cancer & the PROSPECT Trial, as well as non-inferiority trials (released by Two Onc Docs): https://podcasts.apple.com/us/podcast/updates-from-asco23-rectal-cancer-the-prospect-trial/id1616541733?i=1000616604349Episode 2 covering classical hodgkin’s lymphoma & SWOG 1826 as well as “p-values” and what it means when trials say “the median was not reached.” (released by The Fellow on Call): Episode 061: “Paging Heme/Onc: Updates from ASCO 2023” - Classical Hodgkin’s Lymphoma and SWOG 1826Episode 3 covering mRCC & the CONTACT03 Trial, as well as subgroup analysis (released by Two Onc Docs): https://podcasts.apple.com/us/podcast/updates-from-asco23-mrcc-the-contact03-trial/id1616541733?i=1000617519386** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related